Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00700622 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks
A Phase 3 study, sponsored by Mannkind Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 130
- Enrollment target
NCT00700622 is a Phase 3 study that was terminated before completion, run by Mannkind Corporation. The registered enrollment target is 130 participants.
The verdict
NCT00700622, a Phase 3 study, was terminated before completion, sponsored by Mannkind Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 130 participants
- Enrollment target
Study Summary
The objective of this study is to demonstrate that TI® Inhalation Powder combined with Lantus® is as effective as Humalog® combined with Lantus® on HbA1c.
Interventions
- DRUG Technosphere Insulin
- DRUG Insulin glargine
- DRUG Insulin lispro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00700622
The ClinicalTrials.gov registry entry for NCT00700622 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Technosphere Insulin is the first listed.
NCT00700622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00700622 about?
NCT00700622 is a clinical study titled "Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks". The objective of this study is to demonstrate that TI® Inhalation Powder combined with Lantus® is as effective as Humalog® combined with Lantus® on HbA1c.
What is the current status of trial NCT00700622?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 130 participants. The study started on 2008-05. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00700622?
The interventions under investigation include: Technosphere Insulin (DRUG), Insulin glargine (DRUG), Insulin lispro (DRUG).
Who is sponsoring clinical trial NCT00700622?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.